Molecular mechanism of preoperative autologous blood donation and the modified blood-derived PBMCs preservation solution in improving blood-derived PBMCss in diabetic patients

Type-2 diabetes (T2D) is prevalent and significantly impacts the people’s health. At present, there is no specific treatment to prevent the progression of T2D. Furthermore, the clear mechanism of T2D remains unknown. The present study aims to clarify the mechanism of preoperative autologous blood donation (PABD) and the modified blood-derived PBMCs preservation solution in improving blood-derived PBMCss in diabetic patients through regulating the ChREBP-HMGB1-Nrf2 pathway. The present study was conducted to clarify the molecular mechanism of T2D. The general data and blood specimens were obtained from T2D patients. Then, the apoptosis and viability were evaluated. Finally, western blot, flow cytometry assay, immunofluorescence assay, and CCK-8 assay were performed to determine the molecular mechanisms of PABD and the modified blood-derived PBMCs preservation solution in improving blood-derived PBMCss in diabetic patients through regulating the ChREBP-HMGB1-Nrf2 pathway. The present study revealed that PABD and the modified blood-derived PBMCs preservation solution improved T2D patients by downregulating the ChREBP-HMGB1-Nrf2 pathway. This potential target would be of value in alleviating T2D progression. Our findings suggest that dysregulation of the ChREBP–HMGB1–Nrf2 axis may be associated with diabetic pathophysiology, although the precise role of Nrf2 appears to be context-dependent.